Monographie - Palonosetron hydrochloride

Ultimo aggiornamento :
28/04/2024

Palonosetron hydrochloride

Struttura chimica

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Aloxi	Austria, Belgio, Canada, Danimarca, Finlandia, Germania, Giappone, Gran Bretagna, Grecia, Irlanda, Islanda, Italia, Lussemburgo, Malaysia, Norvegia, Paesi Bassi, Polonia, Portogallo, Romania, Spagna, Stati Uniti d’America, Svezia, Svizzera, Turchia, Ungheria
Chepatron	India
Cinvex	Turchia
Factoket	Messico
Lotisa	Turchia
Onicit	Chile, Colombia, Ecuador, Italia, Perù
Palohalt	Chile, Perù
Paloject	Turchia
Palonosetron	Belgio, Chile, Ecuador, Francia, Germania, Gran Bretagna, Spagna, Svizzera
Palostar	India
Palzen	India
Vinaltro	Messico
Viqet	Messico
Vonaxi	Turchia

Bibliografia : Palonosetron hydrochloride

	Tipo	Pubblicazione
1932	Rivista	Trissel LA, Zhang Y. Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate. Int J Pharm Compound 2004 ; 8,5: 398-403.
1936	Rivista	Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl in 4 infusion solusions. Ann Pharmacotherapy 2004 ; 38: 1608-1611.
1940	Rivista	Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 1596-1598.
1950	Rivista	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
1955	Rivista	Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283.
1975	Rivista	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 235-237.
1976	Rivista	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241.
2009	Rivista	Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2016	Rivista	Xu QA, Trissel LA. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1998-2000.
2107	Rivista	Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharm Compound 2006 ; 10: 234-236.
2179	Rivista	Trusley C, Ben M, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 1: 82-85.
2196	Rivista	Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration. Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2214	Rivista	Ben M, Trusley C,Kupiec T.C, Trissel L.A. Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 6: 520-524.
2227	Rivista	Trusley C, Ben M, Kupiec TC, Trissel LA. Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 2: 156-160.
2228	Rivista	Kupiec T, Ben M, Trusley C, Trissel LA. Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration. Int J Pharm Compound 2008 ; 12,2: 170-173.
2279	Rivista	Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2281	Rivista	Ben M, Kupiec T, Trusley C, Trisel LA. Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, Hetastarch in lactated electrolyte, an mannitol injections during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 5: 460-462.
2286	Rivista	Ben M, Trusley C, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 4: 368-371.
2312	Rivista	Trissel L.A, Trusley C, Kupiec T.C, Ben M. Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration. Int J Pharm Compound 2009 ; 13, 1: 78-80.
3459	Rivista	Sun S, Schaller J, Placek J, Duersch B. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3928	Rivista	Wu G, Yeung S, Chen F. Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride. Int J Pharm Compound 2017 ; 21, 1: 76-82.
3981	Rivista	He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D. Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study EJHP 2017 ;24:162?166
4062	Rivista	Wu George, Powers Dan, Yeung S, Chen F, Neelon K. Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection. Int J Pharm Compound 2018 ;22,1:76-85
4310	Rivista	Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M. Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.

Mentions Légales